Amylyx Pharmaceuticals Appoints Jeffrey Trigilio Chief Financial Officer

New Chief Financial Officer Brings Expertise in Business Development and Pipeline Diversification Planning Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the appointment of Jeffrey Trigilio as the company’s first Chief Financial Officer. In this new role, Jeff will lead the company’s financial strategy and business growth and development. Jeff is as an accomplished financial professional with biotechnology experience from operational as well as investment banking and capital markets roles. Prior to joining Amylyx, Jeff most recently served as Vice President of Finance at BlueRock Therapeutics, an engineered cell therapy company focused on neurology, cardiology and immunology with a lead program in Parkinson's disease. While there, he oversaw the finance department and served on BlueRock’s Leadership Team. Jeff helped develop BlueRock’s capital

Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial

Study Meets Primary Endpoint of Slowing of ALS as Measured by the ALSFRS-R December 17, 2019 09:00 AM Eastern Standard Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, and the Sean M. Healey & AMG Center for ALS at Mass [...]

Amylyx Announces Appointment of Debra Canner as Global Head of Human Resources

Passionate HR Leader Brings 20+ Years of Experience to Solidify the Growth of the Company’s Team December 12, 2019 09:30 AM Eastern Standard Time CAMBRIDGE, Mass. (BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., today announced the appointment of Debra Canner as the company’s first Global Head of Human Resources. Deb will serve on Amylyx’ Executive Team, overseeing the [...]

Amylyx Pharmaceuticals Announces Last Patient Completes Last Study Visit in CENTAUR Phase 2 Study of AMX0035 in ALS

October 04, 2019 12:50 PM Eastern Daylight Time CAMBRIDGE, Mass. (BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced that the last participant has completed the planned 24 weeks of study treatment in CENTAUR, a clinical trial assessing the safety and [...]

Amylyx Pharmaceuticals Strengthens Leadership Team with the Appointments of Chief Medical Officer, Chief Commercial Officer and Global Head, Supply Chain

June 24, 2019 10:46 AM Eastern Daylight Time CAMBRIDGE, MA (BUSINESS WIRE) — Amylyx Pharmaceuticals, Inc., today announced three additions to its executive leadership team, appointing industry veterans Patrick Yeramian, M.D., MBA, as chief medical officer, Margaret Olinger, MBA, as chief commercial officer and Tom Holmes as global head, supply chain. These three key appointments serve [...]

Amylyx Pharmaceuticals Announces First Patients Dosed in PEGASUS Phase 2 Trial of AMX0035 in Alzheimer’s Disease and Expansion of the Trial

April 03, 2019 08:30 AM Eastern Daylight Time CAMBRIDGE, MA (BUSINESS WIRE) — Amylyx Pharmaceuticals, Inc., in collaboration with the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation (ADDF) and the Cure Alzheimer’s Fund, today announced the dosing of its first patients in a recently expanded Phase 2 clinical trial (PEGASUS) to assess AMX0035 in individuals with Alzheimer’s [...]

Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMX0035, an oral therapeutic in clinical development for the treatment of amyotrophic lateral sclerosis (ALS). The Company recently began a Phase 2 clinical study, the CENTAUR trial, to evaluate the safety and efficacy of AMX0035 in ALS patients.

Project ALS and Amylyx Enter Collaboration to Test AMX0035

Project ALS and Amylyx Pharmaceuticals today announced a collaboration to undertake pre-clinical studies with Amylyx’s oral compound AMX0035 to advance the understanding of the compound’s neurobiological effects. The studies to be conducted at the Project ALS Pre-Clinical Core at Columbia University’s Motor Neuron Center will complement the company’s recently initiated Phase 2 clinical program of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS).